Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lipocine Inc (LPCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LPCN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.38
1 Year Target Price $7.38
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.78% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.60M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 2 | Beta 1.33 | 52 Weeks Range 2.68 - 8.23 | Updated Date 06/30/2025 |
52 Weeks Range 2.68 - 8.23 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.13% | Operating Margin (TTM) -2226.82% |
Management Effectiveness
Return on Assets (TTM) -17.6% | Return on Equity (TTM) -24.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2329989 | Price to Sales(TTM) 4.79 |
Enterprise Value -2329989 | Price to Sales(TTM) 4.79 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 0.65 | Shares Outstanding 5350360 | Shares Floating 5192520 |
Shares Outstanding 5350360 | Shares Floating 5192520 | ||
Percent Insiders 2.95 | Percent Institutions 9.73 |
Analyst Ratings
Rating 2 | Target Price 7.38 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lipocine Inc
Company Overview
History and Background
Lipocine Inc. is a biopharmaceutical company focused on developing innovative treatments for men's and women's health conditions. Founded in 2002, the company has focused on developing oral delivery technologies to improve the effectiveness and safety of existing and new drugs. Key milestones include the development of TLANDO, an oral testosterone replacement therapy, and its ongoing efforts to develop other hormone-related therapies.
Core Business Areas
- Andrology: Focuses on the development and commercialization of therapies for men's health, particularly testosterone replacement therapy with TLANDO.
- Women's Health: Research and development efforts target unmet needs in women's health, including pre-term birth prevention and potentially female sexual dysfunction.
Leadership and Structure
Lipocine is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, and commercialization divisions.
Top Products and Market Share
Key Offerings
- TLANDO: Oral testosterone replacement therapy (TRT) approved by the FDA. While specific market share data is limited and fluctuates, TLANDO competes with other TRT products like gels, injections and patches. Competitors include AbbVie (AndroGel), Endo International (Aveed), and various generic testosterone products. TLANDO has a potential advantage in administration via oral capsule.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The hormone therapy market is experiencing growth due to an aging population and increasing awareness of hormonal deficiencies.
Positioning
Lipocine is positioned as an innovator in oral hormone therapies, seeking to differentiate itself through improved convenience and safety compared to existing treatments. The company aims to address unmet needs in both men's and women's health.
Total Addressable Market (TAM)
The global testosterone replacement therapy (TRT) market is estimated to be in the billions of dollars annually. Lipocine's TAM is the portion of the TRT market that can be addressed by oral therapies and also segments in women's health. With the launch of TLANDO, Lipocine is positioning itself to capture a share of this market. Women's health including pre-term birth prevention is also expected to be in the billion annually and Lipocine is in the early stage to tap on this market.
Upturn SWOT Analysis
Strengths
- FDA-approved product (TLANDO)
- Proprietary oral delivery technology
- Focus on unmet medical needs
- Potential for differentiation in the hormone therapy market
Weaknesses
- Limited commercial infrastructure
- Dependence on a single product (TLANDO) for revenue generation
- High R&D expenses
- Relatively small market capitalization
Opportunities
- Expansion of TLANDO market share
- Development of new hormone therapies
- Partnerships with larger pharmaceutical companies
- Expansion into international markets
Threats
- Competition from established pharmaceutical companies
- Generic competition
- Regulatory hurdles
- Clinical trial failures
- Negative perceptions of testosterone therapy
Competitors and Market Share
Key Competitors
- ABBV
- AGN
- PRGO
- ENDP
Competitive Landscape
Lipocine faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Lipocine's advantage lies in its proprietary oral delivery technology and focus on unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Lipocine's historical growth is characterized by R&D progress and regulatory approvals, rather than revenue growth until the launch of TLANDO.
Future Projections: Future growth is dependent on the commercial success of TLANDO and the development of new therapies.
Recent Initiatives: Recent initiatives include the commercial launch of TLANDO and ongoing clinical trials for other pipeline products.
Summary
Lipocine is a biopharmaceutical company with an FDA-approved product in TLANDO and promising R&D pipeline in women's health. The company has a strong technology but needs to focus on successfully commercializing TLANDO to compete with its larger competitors. Cash management and partnerships are critical for Lipocine to create shareholder value. The company has high risk but potential upside.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipocine Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2013-10-22 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO Dr. Mahesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.lipocine.com |
Full time employees 16 | Website https://www.lipocine.com | ||
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.